Mark Gardner: The 5 year results from the DYNAMIC trial were shared at ASCO

Mark Gardner, SVP Genomic Medicine and Oncology at Quest Diagnostics, shared on LinkedIn:

“In case you missed it, the 5 year results from the DYNAMIC trial were shared at ASCO. The original findings held up, and the study further demonstrated that surviving ctDNA positive patients who received chemotherapy showed clearance in the blood after treatment. This implies MRD has value for both escalation and de-escalation of adjuvant therapy.”

Read further.
Source: Mark Gardner/LinkedIn